Key facts
- This page summarizes PATRICK DEVAL L's Form 4 filing for Global Blood Therapeutics, Inc..
- 4 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 21 Jun 2021, 16:15.
PATRICK DEVAL L - 17 Jun 2021 Form 4 Insider Report for Global Blood Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 17 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jun 2021, 16:15:43 UTC
- Prior SEC filing
- 17 Jun 2021
- Next SEC filing
- 17 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Miguel Carrillo, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
PATRICK DEVAL L filed Form 4 for Global Blood Therapeutics, Inc. on 21 Jun 2021.
Change
- Previous filing in this sequence was filed on 17 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GBT
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,037
- Change %
- +127%
- Price
- Shares after
- 5,437
- Date
- 17 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GBT
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -3,037
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 17 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,037
- Exercise price
- Footnotes
- F1, F2
GBT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +5,600
- Change %
- Price
- $0.000000
- Shares after
- 5,600
- Date
- 17 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,600
- Exercise price
- $37.09
- Footnotes
- F3
GBT
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +3,600
- Change %
- Price
- $0.000000
- Shares after
- 3,600
- Date
- 17 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,600
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F2
The RSUs vested in a single installment on June 17, 2021.
Footnote F3
The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2021 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).
Footnote F4
The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).
SEC remarks
EXHIBIT 24: Power of Attorney